There's potential for more with a pipeline of drugs in development.
News & Analysis: Seattle Genetics
Despite declines in the broader market, good news lifted shares of these companies.
Sales growth of the biotech's blood cancer drug Adcetris rebounded.
SGEN earnings call for the period ending June 30, 2019.
The biotech is on track to hit its 2019 revenue guidance for Adceris sales to increase 28% to 34%.
SGEN earnings call for the period ending March 31, 2019.
Earnings took down some key companies today.
With shares up 30% year to date, investors may be taking profits.
SGEN earnings call for the period ending December 31, 2018.
Front-line Hodgkin lymphoma turns out to be a tough market to crack.